SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (11821)11/12/2018 7:55:01 PM
From: Miljenko Zuanic  Read Replies (1) of 12215
 
Cheers!
<Among patients with elevated ALT at baseline, those receiving VK2809 demonstrated even greater reductions in mean ALT levels relative to placebo at Weeks 12 and 16. In VK2809-treated patients with elevated baseline ALT (n=13), levels at Week 16 were significantly reduced from baseline by 20.7 U/L (p=0.02). By comparison, patients with elevated baseline ALT levels treated with placebo (n=5) experienced an increase from baseline of 11.6 U/L at Week 16. Mean aspartate aminotransferase (AST) levels among VK2809-treated patients were also reduced relative to placebo at Weeks 12 and 16.>

They did not break ALT/AST reduction level by dose (I guess, very small subjects #), have to believe that 10mg QOD was as good as 10mg QD (LDLc and fat reduction are very similar)....so have no idea why Brian mentioned option for going with 5mg dose (maybe to mimic 10mg QOD, which may show better PD/PK profile)?

Another tid-bit is "novel prodrug" that may bring them needed IP long term right!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News